Table 1.
Baseline characteristics of the two groups before and after PSM.
| Variable | Before PSM | After PSM | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Grading | TACE-A(n=148) | TACE-AP(n=68) | P value | SMD | TACE-A(n=59) | TACE-AP(n=59) | P value | SMD | |
| Gender | Male | 126 (85.1) | 62 (91.2) | 0.313 | 0.188 | 54 (91.5) | 53 (89.8) | 1.000 | 0.058 |
| Female | 22 (14.9) | 6 (8.8) | 5 (8.5) | 6 (10.2) | |||||
| Age | ≤60 | 98 (66.2) | 49 (72.1) | 0.485 | 0.127 | 43 (72.9) | 41 (69.5) | 0.839 | 0.075 |
| >60 | 50 (33.8) | 19 (27.9) | 16 (27.1) | 18 (30.5) | |||||
| Child-Pugh classification | A | 130 (87.8) | 65 (95.6) | 0.124 | 0.284 | 57 (96.6) | 56 (94.9) | 1.000 | 0.084 |
| B | 18 (12.2) | 3 (4.4) | 2 (3.4) | 3 (5.1) | |||||
| PVTT | None | 79 (53.4) | 28 (41.2) | 0.208 | 0.260 | 27 (45.8) | 27 (45.8) | 0.857 | 0.103 |
| Type I+II | 50 (33.8) | 31 (45.6) | 22 (37.3) | 24 (40.7) | |||||
| Type III | 19 (12.8) | 9 (13.2) | 10 (16.9) | 8 (13.6) | |||||
| Metastasis | None | 90 (60.8) | 35 (51.5) | 0.253 | 0.189 | 34 (57.6) | 32 (54.2) | 0.853 | 0.068 |
| Have | 58 (39.2) | 33 (48.5) | 25 (42.4) | 27 (45.8) | |||||
| AFP(ng/mL) | <400 | 87 (58.8) | 42 (61.8) | 0.791 | 0.061 | 32 (54.2) | 35 (59.3) | 0.710 | 0.103 |
| ≥400 | 61 (41.2) | 26 (38.2) | 27 (45.8) | 24 (40.7) | |||||
| HBV | None | 47 (31.8) | 29 (42.6) | 0.161 | 0.277 | 22 (37.3) | 22 (37.3) | 1.000 | <0.001 |
| Have | 101 (68.2) | 39 (57.4) | 37 (62.7) | 37 (62.7) | |||||
| ECOG Score | 0 | 21 (14.2) | 13 (19.1) | 0. 470 | 0.133 | 12 (20.3) | 12 (20.3) | 1.000 | <0.001 |
| 1 | 127 (85.8) | 55 (80.9) | 47 (79.7) | 47 (79.7) | |||||
| TBIL (g/L,mean±SD) | 21.92±10.31 | 21.11±8.44 | 0.574 | 0.186 | 20.65±8.42 | 20.76±8.50 | 0.947 | 0.012 | |
| AlB (μmol/L,mean±SD) | 37.25±4.91 | 38.01±6.90 | 0.358 | 0.126 | 38.11±4.56 | 37.72±7.12 | 0.729 | 0.064 | |
| ALT (U/L,mean±SD) | 46.55±66.25 | 37.94±20.51 | 0.296 | 0.176 | 37.24±20.55 | 37.80±21.61 | 0.886 | 0.027 | |
| Cr (umol/L,mean±SD) | 58.77±11.90 | 61.69±15.08 | 0.126 | 0.215 | 58.54±11.25 | 59.31±11.15 | 0.710 | 0.069 | |
| Number of liver tumors | 1 | 25 (16.9) | 17 (25.0) | 0.373 | 0.201 | 11 (18.6) | 11 (18.6) | 1.000 | <0.001 |
| 2 | 76 (51.4) | 31 (45.6) | 28 (47.5) | 28 (47.5) | |||||
| ≥3 | 47 (31.8) | 20 (29.4) | 20 (33.9) | 20 (33.9) | |||||
| Maximum tumor diameter (mm,mean±SD) | 77.08±45.79 | 70.09±37.57 | 0.272 | 0.167 | 69.41±44.64 | 68.48±37.66 | 0.903 | 0.023 | |
| Number of TACE | 1.95 (1.16) | 2.12 (1.52) | 0.362 | 0.127 | 1.90 (1.12) | 2.14 (1.54) | 0.340 | 0.176 | |
ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoprotein; TBIL, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; Cr, creatinine.